{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:53:13Z","timestamp":1740135193113,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>COVID-19 vaccines are an effective tool to prevent illness due to SARS-CoV-2 infection. However, infection after vaccination still occurs. We evaluated all infections identified among recipients of either the Pfizer-BioNTech or Moderna COVID-19 vaccine in five U.S. states during January\u2013March 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using observational data reported to CDC, we compared the incidence of SARS-CoV-2 infection among vaccinated and unvaccinated persons, and the sex, age, and vaccine product received for individuals with vaccine breakthrough infections to those of the vaccinated\u00a0population using Poisson regression models. We also compared the proportion of vaccine breakthrough cases due to a SARS-CoV-2 variant of concern to data reported to CDC\u2019s national genomic surveillance program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The age-adjusted incidence of reported SARS-CoV-2 infection was 97% lower among vaccinated as compared to unvaccinated persons aged \u2265\u200916\u00a0years (68 vs 2252 cases per 100,000 people). Vaccinated adults aged \u2265\u200985\u00a0years were 1.6 times (95% CI 1.3\u20131.9) as likely to become infected with SARS-CoV-2 than vaccinated adults aged &lt;\u200965\u00a0years. Pfizer-BioNTech COVID-19 vaccine recipients were 1.4 times (95% CI 1.3\u20131.6) as likely to experience infection compared to Moderna COVID-19 recipients. The proportion of infections among vaccinated persons caused by SARS-CoV-2 variants of concern was similar to the proportion of circulating viruses identified as variants of concern in the five states during the same time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Vaccinated persons had a substantially lower incidence of SARS-CoV-2 infection compared to unvaccinated persons. Adults aged \u2265\u200985\u00a0years and Pfizer-BioNTech vaccine recipients had a higher risk of infection following vaccination. We provide an analytic framework for ongoing evaluation of patterns associated with SARS-CoV-2 infection among vaccinated persons using observational surveillance and immunization data. Our findings reinforce the effectiveness of COVID-19 vaccines in preventing infection in real-world settings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07702-x","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T10:04:50Z","timestamp":1662026690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January\u2013March 2021"],"prefix":"10.1186","volume":"22","author":[{"given":"Katrin S.","family":"Sadigh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiersten J.","family":"Kugeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie C.","family":"Massay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Schmoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Milroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson M.","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Sierocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"COVID-19 Vaccine Breakthrough Characterization Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layne","family":"Dorough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiren","family":"Mitruka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Lecy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Castrodale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy M.","family":"Bamberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Alden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andzelika","family":"Rzucidlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin B.","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustus E.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Holladay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin D.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Eziam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb","family":"Wiedeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leisha D.","family":"Nolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"23","key":"7702_CR1","doi-asserted-by":"publisher","first-page":"858","DOI":"10.15585\/mmwr.mm7023e2","volume":"70","author":"A Christie","year":"2021","unstructured":"Christie A, et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 Vaccine\u2014United States, September 6, 2020-May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(23):858\u201364.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7702_CR2","unstructured":"Food and Drug Administration. COVID-19 vaccines. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines. Accessed June 2021."},{"issue":"27","key":"7702_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"7702_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"key":"7702_CR5","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187\u2013201.","journal-title":"N Engl J Med"},{"issue":"19","key":"7702_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, et al. Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"20","key":"7702_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.15585\/mmwr.mm7020e2","volume":"70","author":"T Pilishvili","year":"2021","unstructured":"Pilishvili T, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel\u201433 U.S. sites, January\u2013March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(20):753\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"7702_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.15585\/mmwr.mm7018e1","volume":"70","author":"MW Tenforde","year":"2021","unstructured":"Tenforde MW, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged \u226565 Years\u2014United States, January\u2013March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):674\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10287","key":"7702_CR9","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas EJ, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819\u201329.","journal-title":"Lancet"},{"issue":"13","key":"7702_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"MG Thompson","year":"2021","unstructured":"Thompson MG, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers\u2014Eight U.S. locations, December 2020\u2013March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495\u2013500.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"7702_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/cid\/ciab229","volume":"74","author":"AJ Tande","year":"2021","unstructured":"Tande AJ, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening. Clin Infect Dis. 2021;74(1):59\u201365.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"7702_CR12","doi-asserted-by":"publisher","first-page":"e1376","DOI":"10.1093\/cid\/ciab361","volume":"73","author":"MD Swift","year":"2021","unstructured":"Swift MD, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis. 2021;73(6):e1376\u20139.","journal-title":"Clin Infect Dis"},{"issue":"21","key":"7702_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.15585\/mmwr.mm7021e3","volume":"70","author":"Centers for Disease Control and Prevention","year":"2021","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccine breakthrough infections reported to CDC\u2014United States, January 1\u2013April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7702_CR14","unstructured":"Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. 2021; https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/variant-surveillance\/variant-info.html. Accessed July 2021"},{"issue":"10278","key":"7702_CR15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","volume":"397","author":"A Fontanet","year":"2021","unstructured":"Fontanet A, et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397(10278):952\u20134.","journal-title":"Lancet"},{"key":"7702_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"7702_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"10","key":"7702_CR18","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3201\/eid2610.201800","volume":"26","author":"CR Paden","year":"2020","unstructured":"Paden CR, et al. Rapid, sensitive, full-genome sequencing of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020;26(10):2401\u20135.","journal-title":"Emerg Infect Dis"},{"key":"7702_CR19","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker: Trends in number of COVID-19 cases and deaths in the US reported to CDC, by State\/Territory. 2021; https:\/\/covid.cdc.gov\/covid-data-tracker\/#trends_dailytrendscases. Accessed July 2021."},{"key":"7702_CR20","unstructured":"United States Census Bureau. State population totals and components of change: 2010\u20132019. 2021; https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2010s-state-total.html. Accessed Aug 2021."},{"key":"7702_CR21","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker: Variant proportions. 2021; https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/variant-proportions.html. Accessed July 2021."},{"issue":"23","key":"7702_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.15585\/mmwr.mm7023a3","volume":"70","author":"P Paul","year":"2021","unstructured":"Paul P, et al. Genomic surveillance for SARS-CoV-2 variants circulating in the United States, December 2020\u2013May 2021. MMWR Morb Mortal Wkly Rep. 2021;70(23):846\u201350.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7702_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.15585\/mmwr.mm7032e3","volume":"70","author":"HL Moline","year":"2021","unstructured":"Moline HL, Whitaker M, Deng L, et al. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged \u226565 years\u2014COVID-NET, 13 States, February\u2013April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1088\u201393.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7702_CR24","doi-asserted-by":"crossref","unstructured":"Puranik A et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv, 2021: p. 2021.08.06.21261707.","DOI":"10.1101\/2021.08.06.21261707"},{"issue":"2","key":"7702_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2115463","volume":"386","author":"BA Dickerman","year":"2022","unstructured":"Dickerman BA, et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans. N Engl J Med. 2022;386(2):105\u201315.","journal-title":"N Engl J Med"},{"key":"7702_CR26","doi-asserted-by":"publisher","first-page":"101326","DOI":"10.1016\/j.eclinm.2022.101326","volume":"45","author":"GN Ioannou","year":"2022","unstructured":"Ioannou GN, et al. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: a target trial emulation study in the U.S. Veterans Affairs healthcare system. EClinicalMedicine. 2022;45:101326.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"7702_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6908a1","volume":"69","author":"LA Grohskopf","year":"2020","unstructured":"Grohskopf LA, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2020\u201321 Influenza Season. MMWR Recomm Rep. 2020;69(8):1\u201324.","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"7702_CR28","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac066","volume":"75","author":"LKF Watkins","year":"2022","unstructured":"Watkins LKF, et al. Characteristics of reported deaths among fully vaccinated persons with COVID-19 -United States, January\u2013April 2021. Clin Infect Dis. 2022;75(1):e645\u201352.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"7702_CR29","doi-asserted-by":"publisher","first-page":"EVIDoa2100057","DOI":"10.1056\/EVIDoa2100057","volume":"1","author":"G Paz-Bailey","year":"2022","unstructured":"Paz-Bailey G, et al. Covid-19 rates by time since vaccination during delta variant predominance. NEJM Evid. 2022;1(3):EVIDoa2100057.","journal-title":"NEJM Evid"},{"issue":"37","key":"7702_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.15585\/mmwr.mm7037e1","volume":"70","author":"HM Scobie","year":"2021","unstructured":"Scobie HM, et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status\u201413 U.S. jurisdictions, April 4\u2013July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(37):1284\u201390.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"7702_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.15585\/mmwr.mm7104e2","volume":"71","author":"AG Johnson","year":"2022","unstructured":"Johnson AG, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence\u201425 U.S. jurisdictions, April 4\u2013December 25, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):132\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"7702_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"JM Ferdinands","year":"2022","unstructured":"Ferdinands JM, et al. Waning 2-Dose and 3-Dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations Among adults during periods of Delta and Omicron variant predominance\u2014VISION Network, 10 States, August 2021\u2013January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255\u201363.","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07702-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07702-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07702-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T10:05:33Z","timestamp":1662026733000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07702-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7702"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07702-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This activity was determined to be non-research public health investigation and was conducted in accordance with applicable federal law and CDC policy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"W.M.B. volunteers on the medical advisory boards of First Descents and International School of Denver and receives consulting fees as an individual for COVID-19 prevention assistance from the following entities: Crazy Leg Productions, Feld Entertainment, Cresco Labs, Building Warriors, Museum of Contemporary Art, Clyfford Still Museum, Aurora Mental Health Center, AllHealth Network, Gerson Lehman Group (GLG), InnovAge, Med-Call HealthCare, Vail Resorts, and First Descents. All remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"718"}}